Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

  • Sanoja-Flores, L.
  • Flores-Montero, J.
  • Garces, J.J.
  • Paiva, B.
  • Puig, N.
  • Garcia-Mateo, A.
  • Garcia-Sanchez, O.
  • Corral-Mateos, A.
  • Burgos, L.
  • Blanco, E.
  • Hernandez-Martin, J.
  • Pontes, R.
  • Diez-Campelo, M.
  • Millacoy, P.
  • Rodriguez-Otero, P.
  • Prosper, F.
  • Merino, J.
  • Vidriales, M.B.
  • Garcia-Sanz, R.
  • Romero, A.
  • Palomera, L.
  • Rios-Tamayo, R.
  • Perez-Andres, M.
  • Blanco, J.F.
  • Gonzalez, M.
  • van Dongen, J.J.M.
  • Durie, B.
  • Mateos, M.V.
  • San-Miguel, J.
  • Orfao, A.
Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma cell neoplasms (PCN) using next-generation flow cytometry (NGF) and correlated our findings with the distinct diagnostic and prognostic categories of the disease. Overall, 508 samples from 264 newly diagnosed PCN patients, were studied. CTPC were detected in PB of all active multiple myeloma (MM; 100%), and smoldering MM (SMM) patients (100%), and in more than half (59%) monoclonal gammopathy of undetermined significance (MGUS) cases (p < 0.0001); in contrast, CTPC were present in a small fraction of solitary plasmacytoma patients (18%). Higher numbers of CTPC in PB were associated with higher levels of BM infiltration and more adverse prognostic features, together with shorter time to progression from MGUS to MM (p < 0.0001) and a shorter survival in MM patients with active disease requiring treatment (p <= 0.03). In summary, the presence of CTPC in PB as assessed by NGF at diagnosis, emerges as a hallmark of disseminated PCN, higher numbers of PB CTPC being strongly associated with a malignant disease behavior and a poorer outcome of both MGUS and MM.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

  • Paiva, B.
  • Puig, N.
  • Cedena, M.T.
  • Rosiñol, L.
  • Cordón, L.
  • Vidriales, M.B.
  • Burgos, L.
  • Flores-Montero, J.
  • Sanoja-Flores, L.
  • Lopez-Anglada, L.
  • Maldonado, R.
  • de la Cruz, J.
  • Gutierrez, N.C.
  • Calasanz, M.J.
  • Martin-Ramos, M.L.
  • Garcia-Sanz, R.
  • Martinez-Lopez, J.
  • Oriol, A.
  • Blanchard, M.J.
  • Rios, R.
  • Martin, J.
  • Martinez-Martinez, R.
  • Sureda, A.
  • Hernandez, M.T.
  • de la Rubia, J.
  • Krsnik, I.
  • Moraleda, J.M.
  • Palomera, L.
  • Bargay, J.
  • Van Dongen, J.J.M.
  • Orfao, A.
  • Mateos, M.V.
  • Blade, J.
  • San-Miguel, J.F.
  • Lahuerta, J.J.
PURPOSE: Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG). PATIENTS AND METHODS: In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM had longitudinal assessment of MRD after six induction cycles with bortezomib, lenalidomide, and dexamethasone (VRD), autologous transplantation, and two consolidation courses with VRD. MRD was assessed in 1, 100 bone marrow samples from 397 patients; the 61 patients without MRD data discontinued treatment during induction and were considered MRD positive for intent-to-treat analysis. The median limit of detection achieved by NGF was 2.9 × 10-6. Patients received maintenance (lenalidomide ± ixazomib) according to the companion PETHEMA/GEM2014MAIN trial. RESULTS: Overall, 205 (45%) of 458 patients had undetectable MRD after consolidation, and only 14 of them (7%) have experienced progression thus far; seven of these 14 displayed extraosseous plasmacytomas at diagnosis and/or relapse. Using time-dependent analysis, patients with undetectable MRD had an 82% reduction in the risk of progression or death (hazard ratio, 0.18; 95% CI, 0.11 to 0.30; P < .001) and an 88% reduction in the risk of death (hazard ratio, 0.12; 95% CI, 0.05 to 0.29; P < .001). Timing of undetectable MRD (after induction v intensification) had no impact on patient survival. Attaining undetectable MRD overcame poor prognostic features at diagnosis, including high-risk cytogenetics. By contrast, patients with Revised International Staging System III status and positive MRD had dismal progression-free and overall survivals (median, 14 and 17 months, respectively). Maintenance increased the rate of undetectable MRD by 17%. CONCLUSION: The IMWG flow MRD-negative response criterion is highly applicable and sensitive to evaluate treatment efficacy in MM.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Otros (Other)

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

  • Cuenca, I.
  • Alameda, D.
  • Sanchez-Vega, B.
  • Gomez-Sanchez, D.
  • Alignani, D.
  • Lasa, M.
  • Onecha, E.
  • Lecumberri, R.
  • Prosper, F.
  • Ocio, E.M.
  • González, M.E.
  • García de Coca, A.
  • De La Rubia, J.
  • Gironella, M.
  • Palomera, L.
  • Oriol, A.
  • Casanova, M.
  • Cabañas, V.
  • Taboada, F.
  • Pérez-Montaña, A.
  • De Arriba, F.
  • Puig, N.
  • Carreño-Tarragona, G.
  • Barrio, S.
  • Enrique de la Puerta, J.
  • Ramirez-Payer, A.
  • Krsnik, I.
  • Bargay, J.J.
  • Lahuerta, J.J.
  • Mateos, M.V.
  • San-Miguel, J.F.
  • Paiva, B.
  • Lopez, J.M.
To the Editor: Sequence-based analysis has come to play an integral role in many hematological malignancies [1], but disorders such as systemic light-chain (AL) amyloidosis remain poorly characterized due to its low incidence and small tumor size [2, 3]. Thus, greater knowledge about the immunogenetic landscape of AL amyloidosis is required since, for example, potential differences between the genomic profiles of AL amyloidosis and multiple myeloma (MM) could help identifying patients with monoclonal gammopathies at greater risk of developing AL amyloidosis and monitor presymptomatic organ damage [4, 5]. To gain further insight into the immunogenetic landscape of AL amyloidosis, we performed whole-exome sequencing (WES) on highly purified bone marrow clonal plasma cells (PCs) isolated by fluorescence activation cell sorting (FACS) based on patient-specific aberrant phenotypes. A total of 27 patients with confirmed new diagnosis of AL amyloidosis based on the presence of amyloid-related systemic syndrome, positive amyloid tissue staining with Congo red, restricted light-chain deposition by immunohistochemistry or mass spectometry, and evidence of PC clonality were investigated. Patients’ demographics and clinical characteristics are described in Supplementary Table 1. PCs were collected and processed in triplicates followed by whole genome amplification of samples with genomic DNA amounts <50 ng (Supplementary Table 2). Afterwards, library construction, exome enrichment, and sequencing were performed individually. An overall average depth of 63× and mean on-target coverage of 84% were obtained. Data were deposited in the Sequence Read Archive of the NCBI (http://www.ncbi.nlm.nih.gov/sra) under the PRJNA596656 access number...